Clinical Trials Logo
  1. Home
  2. Alzheimer Disease
  3. NCT00036114
  4. Details
NCT00036114 Clinical Trial

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Alzheimer Disease Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00036114
Other study ID # CN138-004
Secondary ID
Status Completed
Phase Phase 3
First received May 7, 2002
Last updated November 7, 2013
Start date March 2000
Est. completion date August 2003

Study information
Verified date April 2011
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date August 2003
Est. primary completion date August 2003
Accepts healthy volunteers No
Gender Both
Age group 55 Years to 95 Years
Eligibility Inclusion Criteria:

- Institutionalized patients with Alzheimer's

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• aripiprazole

Locations
Country Name City State
United States Local Institution Albany New York
United States Local Institution Atlanta Georgia
United States Local Institution Augusta Georgia
United States Local Institution Austin Texas
United States Local Institution Baltimore Maryland
United States Local Institution Beachwood Ohio
United States Local Institution Bennington Vermont
United States Local Institution Cerritos California
United States Local Institution Charlottesville Virginia
United States Local Institution Dallas Texas
United States Local Institution Denver Colorado
United States Local Institution Granada Hills California
United States Local Institution Hamden Connecticut
United States Local Institution Hershey Pennsylvania
United States Local Institution Honolulu Hawaii
United States Local Institution Lawrence New York
United States Local Institution Los Angeles California
United States Local Institution Lyons New Jersey
United States Local Institution Macon Georgia
United States Local Institution Miami Florida
United States Local Institution Montrose New York
United States Local Institution New Orleans Louisiana
United States Local Institution Newton Center Massachusetts
United States Local Institution North Chicago Illinois
United States Local Institution North Miami Beach Florida
United States Local Institution Northport New York
United States Local Institution Portland Oregon
United States Local Institution Raleigh North Carolina
United States Local Institution San Antonio Texas
United States Local Institution San Diego California
United States Local Institution Scottsdale Arizona
United States Local Institution Seattle Washington
United States Local Institution Shreveport Louisiana
United States Local Institution Springfield Illinois
United States Local Institution Springfield Massachusetts
United States Local Institution Torrance California
United States Local Institution Tuscaloosa Alabama
United States Local Institution Wellesley Hills Massachusetts
United States Local Institution West Palm Beach Florida
United States Local Institution White Plains New York
United States Local Institution Wichita Falls Texas

Sponsors (1)
Lead Sponsor Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A

External Links